Nicola S Meagher, Linyuan Wang, Peter F Rambau, Maria P Intermaggio, David G Huntsman, Lynne R Wilkens, Mona A El-Bahrawy, Roberta B Ness, Kunle Odunsi, Helen Steed, Esther Herpel, Michael S Anglesio, Bonnie Zhang, Neil Lambie, Anthony J Swerdlow, Jan Lubiński, Robert A Vierkant, Ellen L Goode, Usha Menon, Aleksandra Toloczko-Grabarek, Oleg Oszurek, Sanela Bilic, Aline Talhouk, Montserrat García-Closas, Qin Wang, Adeline Tan, Rhonda Farrell, Catherine J Kennedy, Mercedes Jimenez-Linan, Karin Sundfeldt, John L Etter, Janusz Menkiszak, Marc T Goodman, Paul Klonowski, Yee Leung, Stacey J Winham, Kirsten B Moysich, Sabine Behrens, Tomasz Kluz, Robert P Edwards, Jacek Gronwald, Francesmary Modugno, Brenda Y Hernandez, Christine Chow, Linda E Kelemen, Gary L Keeney, Michael E Carney, Yanina Natanzon, Gregory Robertson, Raghwa Sharma, Simon A Gayther, Jennifer Alsop, Hugh Luk, Chloe Karpinskyj, Ian Campbell, Peter Sinn, Aleksandra Gentry-Maharaj, Penny Coulson, Jenny Chang-Claude, Mitul Shah, Martin Widschwendter, Katrina Tang, Minouk J Schoemaker, Jennifer M Koziak, Linda S Cook, James D Brenton, Frances Daley, Björg Kristjansdottir, Constantina Mateoiu, Melissa C Larson, Paul R Harnett, Audrey Jung, Anna deFazio, Kylie L Gorringe, Paul D P Pharoah, Parham Minoo, Colin Stewart, Oliver F Bathe, Xianyong Gui, Paul Cohen, Susan J Ramus, Martin Köbel
Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal neoplasms by histology alone. The expected immunoprofile of a suspected metastatic lower gastrointestinal tumor is CK7- /CK20+ /CDX2+ /PAX8- . This study assesses the addition of a novel marker SATB2, to improve the diagnostic algorithm. A test cohort included 155 ovarian mucinous tumors (105 carcinomas and 50 borderline tumors) and 230 primary lower gastrointestinal neoplasms (123 colorectal adenocarcinomas and 107 appendiceal neoplasms)...
December 2019: Modern Pathology